HEALWELL AI Inc., a Toronto-based healthcare artificial intelligence company, has issued a clarifying press release regarding its November 3, 2025, announcement of strategic divestments. The Ontario Securities Commission requested this additional information as part of an ongoing disclosure review, aiming to provide context on the company’s revenue run-rate and Adjusted EBITDA.
In its previous release, HEALWELL described its completion of three strategic transactions, including the sale of two non-core businesses and the contribution of two additional non-core operations to a new clinical research joint venture. This restructuring is intended to position HEALWELL as a focused provider of digital software-as-a-service (SaaS) solutions, primarily targeting health systems and large enterprises globally. The company indicated a projected annual revenue run-rate of approximately $120 million and profitability on an Adjusted EBITDA basis, statements characterized as forward-looking information under Canadian securities laws.
The company emphasized that this forward-looking information was based on its historical financial performance. HEALWELL reported quarterly revenue from continuing operations of $30.4 million for the third quarter of 2025, marking a significant increase of 354% from $6.7 million in the same period of 2024. The company also noted a positive Adjusted EBITDA of $0.7 million for Q3 2025, a contrast to an Adjusted EBITDA loss of $2.8 million in Q3 2024, representing its second consecutive quarter of positive Adjusted EBITDA since acquiring Orion Health in April 2025.
HEALWELL’s forward-looking statements depend on several assumptions, such as the ability to maintain relationships with commercial partners, the continued adoption of its software solutions, and compliance with evolving regulatory standards. The company acknowledged inherent risks and uncertainties that could lead to actual results differing materially from projections. Factors impacting these outcomes include changes in customer demand, competition in the healthcare software market, and the ability to recruit and retain key personnel.
Moreover, the company clarified earlier statements regarding its AI capabilities and market positioning, asserting that claims of “industry-leading and third-party validated AI solutions” were intended to reflect external recognition rather than financial performance. HEALWELL and its subsidiaries, particularly Pentavere Research Group Inc., have received acclaim for their contributions to healthcare accessibility and preventative care. Pentavere’s DARWEN™ AI platform, which extracts real-world evidence from unstructured clinical data, has garnered significant industry accolades, including the prestigious Prix Galien USA 2024 award for Best Digital Health Startup.
HEALWELL’s AI solutions are currently under evaluation or deployed by public health organizations, healthcare systems, and enterprise customers, highlighting their real-world operational efficacy. Peer-reviewed studies in notable journals, such as JAMA Otolaryngology and the Journal of Clinical Oncology, have validated the effectiveness of HEALWELL’s technologies in clinical settings.
This clarification aims to aid investors and stakeholders in understanding HEALWELL’s strategic direction and financial prospects amidst a rapidly evolving landscape in healthcare AI. As the company continues to innovate and expand its service offerings, it remains focused on delivering advanced clinical decision support systems that enhance patient health outcomes through early disease detection and intervention.
HEALWELL AI Inc. trades on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange as “HWAIF.” For more information, interested parties are encouraged to visit the company’s website at healwell.ai.
See also
AI Transitions to Profit Engine as Investment Surges; Concerns Over Bubble Risks Grow
JD Sports Launches Cutting-Edge Tech Innovation Centre to Enhance Retail Experience
Bank of America Warns of Wage Concerns Amid AI Spending Surge
OpenAI Restructures Amid Record Losses, Eyes 2030 Vision
